Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
James Udelson MD

James E. Udelson MD

Chief, Division of Cardiology; Director, Nuclear Cardiology Laboratory, Tufts Medical Center; Professor, Medicine and Radiology, Tufts University School of Medicine, Boston, Massachusetts

Dr. James Udelson is Chief of the Division of Cardiology as well as Director of Nuclear Cardiology at Tufts Medical Center. He is a Professor of Medicine and Radiology at Tufts University School of Medicine in Boston.

He has been the recipient of several NIH grants for studies of the use of cardiac imaging to better understand the physiology of left ventricular function and to favorably influence clinical decision–making. He has directed and/or participated in numerous clinical trials on heart failure and cardiac imaging, focusing on the role of new therapies and how they affect remodeling, physiology, function, and outcomes.

Dr. Udelson has been involved in editorial capacities for several high-impact journals including Circulation, Circulation: Heart Failure, JAMA Cardiology, the Journal of the American College of Cardiology (JACC), and the Journal of Nuclear Cardiology, among others, and has served on numerous national guideline and appropriate-use criteria writing groups. He has participated in a leadership capacity for professional organizations including the American Society of Nuclear Cardiology, the American College of Cardiology (ACC), and the Heart Failure Society of America. Additionally, he has served on several FDA advisory panels.

Disclosures

  • Advisory boards/trial committees: Bayer; MedTrace; LivaNova; scPharmaceuticals; Cardurion; Imbria; Abiomed; Merck; Cytokinetics; Medtronic; Reprieve Cardiovascular; Alleviant Medical

Recent Contributions to PracticeUpdate:

  1. Echo Findings in US Children With MIS-C and COVID-19
  2. Imaging of Clinically Unrecognized Myocardial Fibrosis in Patients With Suspected Coronary Artery Disease
  3. PET/CT Marker of Depression in Chronic Systolic HF
  4. Cardiac Manifestations of COVID-19 by Echocardiography
  5. Cardiac Involvement in Recovered COVID-19 Patients Identified by MRI
  6. Vericiguat in Patients With HFrEF
  7. ACC: New Data From the ISCHEMIA Trial on Revascularization vs Optimal Medical Therapy
  8. ACC: Mavacamten for Hypertrophic Cardiomyopathy
  9. ACC: Results of the VICTORIA Trial on Vericiguat in Heart Failure
  10. ACC: New Data From ISCHEMIA-CKD on Pursuing Revascularization Strategies in CKD Patients

Most Read This Week

Recently Updated